Peiffer-Smadja, N.; Bridier-Nahmias, A.; Ferré, V.M.; Charpentier, C.; Garé, M.; Rioux, C.; Allemand, A.; Lavallée, P.; Ghosn, J.; Kramer, L.;
et al. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses 2021, 13, 1642.
https://doi.org/10.3390/v13081642
AMA Style
Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L,
et al. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021; 13(8):1642.
https://doi.org/10.3390/v13081642
Chicago/Turabian Style
Peiffer-Smadja, Nathan, Antoine Bridier-Nahmias, Valentine Marie Ferré, Charlotte Charpentier, Mathilde Garé, Christophe Rioux, Aude Allemand, Philippa Lavallée, Jade Ghosn, Laura Kramer,
and et al. 2021. "Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2" Viruses 13, no. 8: 1642.
https://doi.org/10.3390/v13081642
APA Style
Peiffer-Smadja, N., Bridier-Nahmias, A., Ferré, V. M., Charpentier, C., Garé, M., Rioux, C., Allemand, A., Lavallée, P., Ghosn, J., Kramer, L., Descamps, D., Yazdanpanah, Y., & Visseaux, B.
(2021). Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses, 13(8), 1642.
https://doi.org/10.3390/v13081642
